These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33482308)

  • 1. Opioids and cancer prognosis: A summary of the clinical evidence.
    Ramirez MF; Gorur A; Cata JP
    Neurosci Lett; 2021 Feb; 746():135661. PubMed ID: 33482308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Perioperative Opioids on Cancer-Relevant Circulating Parameters: Mu Opioid Receptor and Toll-Like Receptor 4 Activation Potential, and Proteolytic Profile.
    Xie N; Matigian N; Vithanage T; Gregory K; Nassar ZD; Cabot PJ; Shaw PN; Kirkpatrick CMJ; Cao KL; Sturgess D; Parat MO
    Clin Cancer Res; 2018 May; 24(10):2319-2327. PubMed ID: 29511031
    [No Abstract]   [Full Text] [Related]  

  • 3. The Role of Opioids and Their Receptors in Urological Malignancy: A Review.
    Lec PM; Lenis AT; Golla V; Brisbane W; Shuch B; Garraway IP; Reiter RE; Chamie K
    J Urol; 2020 Dec; 204(6):1150-1159. PubMed ID: 32516030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients.
    Viet CT; Dang D; Aouizerat BE; Miaskowski C; Ye Y; Viet DT; Ono K; Schmidt BL
    J Pain; 2017 Sep; 18(9):1046-1059. PubMed ID: 28456745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids and Cancer: Current Understanding and Clinical Considerations.
    Sah D; Shoffel-Havakuk H; Tsur N; Uhelski ML; Gottumukkala V; Cata JP
    Curr Oncol; 2024 May; 31(6):3086-3098. PubMed ID: 38920719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the mu-Opioid Receptor for Cancer Treatment.
    Zhang H; Zhou D; Gu J; Qu M; Guo K; Chen W; Miao C
    Curr Oncol Rep; 2021 Aug; 23(10):111. PubMed ID: 34342720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Pain, Opioids, and the Mu-opioid Receptor on Progression and Survival in Patients With Newly Diagnosed Stage IV Pancreatic Cancer.
    Steele GL; Dudek AZ; Gilmore GE; Richter SA; Olson DA; Eklund JP; Zylla DM
    Am J Clin Oncol; 2020 Aug; 43(8):591-597. PubMed ID: 32482952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review.
    Lefkowits C; Buss MK; Ramzan AA; Fischer S; Urban RR; Fisher CM; Duska LR
    Gynecol Oncol; 2018 May; 149(2):394-400. PubMed ID: 29472016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
    Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
    BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management.
    Lam LH; Pirrello RD; Ma JD
    J Clin Pharmacol; 2016 Jul; 56(7):785-93. PubMed ID: 26626053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
    Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
    Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.
    Zylla D; Gourley BL; Vang D; Jackson S; Boatman S; Lindgren B; Kuskowski MA; Le C; Gupta K; Gupta P
    Cancer; 2013 Dec; 119(23):4103-10. PubMed ID: 24104703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of current opioid drugs focusing on MOR-related strategies.
    Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
    Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of opioid utility in cancer pain populations.
    Wong SS; Cheung CW
    Ann Palliat Med; 2020 Mar; 9(2):558-570. PubMed ID: 32233627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining opioids and non-opioids for pain management: Current status.
    Li JX
    Neuropharmacology; 2019 Nov; 158():107619. PubMed ID: 31029588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility.
    Ramzan AA; Fischer S; Buss MK; Urban RR; Patsner B; Duska LR; Fisher CM; Lefkowits C
    Gynecol Oncol; 2018 May; 149(2):401-409. PubMed ID: 29544707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review.
    Nijland L; Schmidt P; Frosch M; Wager J; Hübner-Möhler B; Drake R; Zernikow B
    Support Care Cancer; 2019 Jan; 27(1):33-42. PubMed ID: 30056529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.
    Oladosu FA; Conrad MS; O'Buckley SC; Rashid NU; Slade GD; Nackley AG
    PLoS One; 2015; 10(8):e0135711. PubMed ID: 26270813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and Cancer Mortality.
    Amaram-Davila J; Davis M; Reddy A
    Curr Treat Options Oncol; 2020 Feb; 21(3):22. PubMed ID: 32095929
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.